Insider Trading Report for BridgeBio Pharma, Inc.

This filing details stock transactions by Neil Kumar, CEO of BridgeBio Pharma, Inc. (BBIO). On April 9th and 10th, 2026, Kumar executed several sales of the company's common stock through Rule 10b5-1 trading plans. These sales were conducted via various trusts where Kumar serves as a co-trustee, including the Kumar Haldea Family Irrevocable Trust and the Kumar Haldea Revocable Trust. The transactions involved a total of 84,900 shares sold at prices ranging from $73.15 to $76.18 per share. Following these transactions, Kumar's direct ownership of BBIO stock decreased, while his indirect ownership through these trusts saw adjustments, with post-transaction holdings reported for each sale. The filing indicates that these sales were part of pre-arranged trading plans and that Kumar disclaims beneficial ownership beyond his pecuniary interest.